Navigation Links
Telik Announces Fourth Quarter And 2012 Year End Financial Results And 2013 Financial Guidance
Date:3/15/2013

rome (MDS).  Orphan designation grants potential US market exclusivity to a drug for the treatment of a specified condition for a period of seven years following FDA marketing approval.  Additional potential benefits of orphan designation include development grants, tax credits related to clinical trial expenses, protocol development assistance and exemption from FDA user fees. 

Results of clinical trials with Telintra were reported in peer reviewed medical publications including:

  • "Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)," Raza, A., et al., Journal of Hematology & Oncology 2012, 5:18 doi:10.1186/1756-8722-5-18; 30 April 2012. Significant findings of the study included multilineage responses and good tolerability, supporting the further development of the Telintra and Revlimid® combination in MDS as well as in other hematologic malignancies where Revlimid is a standard of care.
  • "Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome," Galili, N. et al., Journal of Hematology & Oncology 2012, 5:20 doi:10.1186/1756-8722-5-20; 6 May 2012. A gene marker analysis was performed using RNA available from 30 patients enrolled in a Phase 2 Telintra clinical trial. Pathway analysis of the response profile revealed that the genes comprising the jun-N-terminal kinase/c-JUN molecular pathway, which is known to be influenced by Telintra, were under-expressed in responders and over-expressed in non-responders, providing additional support for the novel mechanism of action of Telintra and a potential basis for a companion diagnostic.
  • "Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, for Treatment of Patients with Myeloid Growth Factor-Resistant Idiopathic Chronic Neutropenia (ICN)," by '/>"/>

  • SOURCE Telik, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Telik Announces Third Quarter 2012 Financial Results
    2. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
    3. ULURU Inc. Announces Closing Of $440,000 Private Placement
    4. Cardica Announces Proposed Public Offering of Common Stock
    5. PAREXEL International Provides Update On Share Repurchase Program, Announces A New $50 Million Accelerated Share Repurchase Agreement And A New $50 Million 10b5-1 Trading Plan
    6. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spectrum Pharmaceuticals, Inc.
    7. Simbionix Announces License Agreement for Surgical Videos
    8. BioTrends Announces the Continuation of a Syndicated Report Series: TreatmentTrends: CKD Stages 1-5ND
    9. Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
    10. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
    11. PDI, Inc. Announces $17 Million Multi-Year Sales Contract
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
    (Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
    (Date:1/14/2014)... 2014   NuAire , a manufacturer of ergonomically designed laboratory ... Koki of Japan to sell and ... . NuAire will utilize its network of sales professionals throughout ... to offer assistance in application use, product benefits and ...
    Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
    ... VIVUS, Inc. (NASDAQ: VVUS ) today announced that ... Congress on Obesity (ECO) in Istanbul, Turkey.  ECO is the ... of Obesity (EASO). ECO is regularly attended by more than ... be the most important annual scientific event on obesity in ...
    ... 2011 MicroVention-Terumo, Inc., a leader in developing, ... the final 18-month follow-up data in a landmark ... Packing Study (HELPS) published in The Lancet ... treating cerebral aneurysms reduced recurrence and retreatment rates ...
    Cached Medicine Technology:Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity 2Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity 3Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity 4Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity 5Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumo's HydroCoil® Embolic System for Treatment of Cerebral Aneurysms 2Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumo's HydroCoil® Embolic System for Treatment of Cerebral Aneurysms 3Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumo's HydroCoil® Embolic System for Treatment of Cerebral Aneurysms 4
    (Date:4/17/2014)... It,s estimated that as many as 10 million older ... of loneliness and isolation. , However, new research ... retired older Americans for six years found that ... of depression by more than 30 percent. , "That,s ... State University professor of telecommunication, information studies and media ...
    (Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
    (Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
    (Date:4/17/2014)... researchers at UC Davis has shown that the cyclin ... cell division, also boosts the mitochondrial activity to power ... has been shown to perform both jobs. This newfound ... control cellular energy production, potentially advancing cancer care and ... the journal Developmental Cell . , "These proteins ...
    (Date:4/17/2014)... by Cesar A. Arias, M.D., Ph.D., at The University ... identified a new superbug that caused a bloodstream infection ... April 17 issue of The New England Journal ... of a class of highly-resistant bacteria known as methicillin-resistant ... major cause of hospital and community-associated infections. The superbug ...
    Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2
    ... Nov. 19 Have you ever asked yourself, "What in the ... it,s safe to give your puppy a leftover turkey drumstick - ... , , To address these ... Association (AVMA) today launched a new podcast series, "Chew on This," ...
    ... “OneMedForum 2009” finance conference for emerging medtech companies ... Francisco at the Sir Francis Drake Hotel. The ... to be a vital resource for emerging medtech ... two-day OneMedForum event will include industry-focused panel sessions, ...
    ... PC Brands, a,California-based manufacturer of nutrition bars, today ... shelf stable all-natural bars. The,"on the go" bars ... does not require refrigeration. , ... in a 90-calorie Yogurt,Fruit and Nut with Cranberries, Almonds ...
    ... study by researchers at the Bradley Hasbro Children,s Research Center ... among teens and young adults particularly those who have ... that show anal sex rates among adults doubled between the ... the American Journal of Public Health , is among ...
    ... of thousands of Americans are injured or die on our nation,s ... scores in a new roadway safety scorecard released today by the ... and South Dakota received the lowest scores. The report, ... for Injury Prevention , examines roadway safety laws in all 50 ...
    ... developer of voice solutions for healthcare, has been ... to help researchers assess the impact of automated ... on commonly prescribed medications. Using interactive voice response ... healthcare providers to evaluate real time patient data. ...
    Cached Medicine News:Health News:AVMA Launches 'Chew on This' Podcast Series on Food Safety 2Health News: OneMedPlace announces "OneMedForum 2009" finance conference for emerging medtech companies : Second annual event to be held January 13-14, 2009, in San Francisco 2Health News:PC Brands Introduces Great Tasting Shelf-Stable Nutrition Bar With Probiotics 2Health News:More at-risk teens and young adults engaging in anal intercourse 2Health News:Oregon, Washington State Doing the Most to Promote Roadway Safety, According to New Emergency Nurses Association National Scorecard 2Health News:Oregon, Washington State Doing the Most to Promote Roadway Safety, According to New Emergency Nurses Association National Scorecard 3Health News:Brigham and Women's Researchers Partner with Vocantas to use CallAssure in Clinical Research Study 2
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    Medicine Products: